BioNTech to Present Oncology Pipeline Data at AACR Meeting
Ticker: BNTX · Form: 6-K · Filed: Mar 11, 2024 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Mar 11, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trials, oncology, data-release
TL;DR
BioNTech dropping new cancer drug data at AACR next month.
AI Summary
On March 11, 2024, BioNTech SE announced its intention to present clinical trial data for several oncology pipeline candidates at the American Association for Cancer Research (AACR) Annual Meeting. The presentation will include data on its mRNA-based therapies, highlighting progress in its cancer treatment development.
Why It Matters
This presentation showcases BioNTech's advancements in its oncology pipeline, potentially impacting future cancer treatment development and investor confidence.
Risk Assessment
Risk Level: low — This filing is an announcement of data presentation, not a financial event or material change in business operations.
Key Players & Entities
- BioNTech SE (company) — Registrant
- American Association for Cancer Research (AACR) Annual Meeting (company) — Event for data presentation
- March 11, 2024 (date) — Announcement date
FAQ
What specific oncology pipeline candidates will BioNTech present data on?
The filing states that data for 'selected candidates' from its oncology pipeline will be presented, but does not list the specific names of these candidates.
When will the AACR Annual Meeting take place?
The filing does not specify the exact dates of the AACR Annual Meeting, only that BioNTech will present during the month of March 2024.
What type of therapies will be highlighted in the presentation?
The filing indicates that the presentation will include data on BioNTech's 'mRNA-based therapies'.
Is this announcement related to any new drug approvals or regulatory submissions?
No, this filing is an announcement of clinical trial data presentation at a scientific meeting, not a regulatory submission or approval.
Where is BioNTech SE headquartered?
BioNTech SE is headquartered in Mainz, Germany, with its principal executive offices located at An der Goldgrube 12, D-55131 Mainz.
Filing Stats: 255 words · 1 min read · ~1 pages · Grade level 14 · Accepted 2024-03-11 09:04:00
Filing Documents
- form6-kaacr11mar2024.htm (6-K) — 13KB
- a99_1240311xbntxprxaacr202.htm (EX-99.1) — 26KB
- image_0.jpg (GRAPHIC) — 15KB
- 0001776985-24-000017.txt ( ) — 60KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On March 11, 2024, BioNTech SE announced that it will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California, from April 5-10, 2024. The press release is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Dr. Sierk Poetting Name Dr. Sierk Poetting Title Chief Operating Officer Date March 11, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech to Present Clinical Data Updates For Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024